# Saccharomyces cerevisiae RC 12

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-rc-12
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** S. cerevisiae RC 12, RC-12 strain, Saccharomyces cerevisiae strain RC 12, Clinical yeast strain RC 12, Probiotic yeast RC 12

## Overview

Saccharomyces cerevisiae RC 12 is a specific yeast strain whose cell wall components — notably beta-glucans and mannoproteins — modulate gut microbiota composition and exert [antimicrobial](/ingredients/condition/immune-support) activity against enteric pathogens. Its primary mechanisms involve [prebiotic](/ingredients/condition/gut-health) fermentation byproducts that stimulate beneficial bacteria and direct membrane-disrupting effects on pathogenic Escherichia coli strains.

## Health Benefits

• Promotes beneficial gut bacteria growth (Bifidobacterium and Lactobacillus) and increases short-chain fatty acid production in simulated gut models (in vitro evidence only)
• Reduces pathogenic ETEC bacteria viability by damaging membrane integrity and suppressing virulence genes in digestive simulations (preclinical evidence)
• Inhibits Gardnerella bacterial load by 90% and reduces biofilm formation in vaginal infection models (animal studies only)
• Enhances immune cell activity by boosting PMN cell ROS production against Candida albicans (preclinical evidence)
• Demonstrates survival through harsh digestive conditions with 41-57% hydrophobicity and up to 92% auto-aggregation properties (in vitro data)

## Mechanism of Action

The [beta-glucan](/ingredients/condition/immune-support) and mannoprotein fractions in the RC 12 cell wall act as fermentable substrates, selectively stimulating Bifidobacterium and Lactobacillus species to produce short-chain fatty acids (SCFAs) such as butyrate and propionate, which lower luminal pH and support colonocyte integrity. Simultaneously, RC 12 cell wall components physically interact with the outer membrane of enterotoxigenic Escherichia coli (ETEC), compromising membrane integrity through disruption of lipopolysaccharide architecture. This dual action also downregulates ETEC virulence gene expression, including genes encoding heat-labile and heat-stable enterotoxins, reducing the organism's pathogenic capacity.

## Clinical Summary

Current evidence for Saccharomyces cerevisiae RC 12 is derived primarily from in vitro simulated gut fermentation models and cell-based assays rather than randomized controlled trials in humans, which significantly limits the strength of available conclusions. In vitro fermentation studies have demonstrated measurable increases in Bifidobacterium and Lactobacillus populations alongside elevated SCFA output, while separate digestive simulation experiments quantified reductions in ETEC viability and suppression of virulence gene transcription. No large-scale human clinical trials have been published specifically on the RC 12 strain to confirm these findings translate to in vivo efficacy. Consumers should treat current data as hypothesis-generating rather than clinically conclusive.

## Nutritional Profile

Saccharomyces cerevisiae RC 12 is a probiotic yeast strain with nutritional composition broadly consistent with S. cerevisiae species, though strain-specific concentrations may vary. Protein content: approximately 40–50% of dry weight, comprising all essential amino acids including lysine (~6–8 g/100g protein) and methionine (limited, ~1–2 g/100g protein). Carbohydrates: 35–45% of dry weight, predominantly as cell wall beta-glucans (1,3- and 1,6-linkages, ~25–35% of dry weight) and mannan polysaccharides (~15–20% of dry weight), which contribute to [prebiotic](/ingredients/condition/gut-health) and [immunomodulatory](/ingredients/condition/immune-support) activity. Lipids: 4–7% of dry weight, including ergosterol (provitamin D2 precursor, ~1–2 mg/g dry weight) and unsaturated fatty acids (oleic and linoleic acid predominant). B-vitamins are notable: thiamine (B1, ~10–15 mg/100g), riboflavin (B2, ~4–6 mg/100g), niacin (B3, ~40–60 mg/100g), pantothenic acid (B5, ~10–20 mg/100g), pyridoxine (B6, ~3–5 mg/100g), and folate (B9, ~1–3 mg/100g dry weight). Minerals: zinc (~8–12 mg/100g), selenium (variable, strain- and growth-medium-dependent, typically 0.1–0.3 mg/100g in standard conditions), iron (~2–5 mg/100g), magnesium (~200–300 mg/100g), and phosphorus (~1,400–1,800 mg/100g). Bioactive compounds: [glutathione](/ingredients/condition/detox) (~1–5 mg/g dry weight, [antioxidant](/ingredients/condition/antioxidant)), coenzyme Q (ubiquinol precursor), and nucleotides (RNA-derived, ~6–12% of dry weight). Bioavailability note: As an intact yeast cell preparation, cell wall integrity may reduce direct absorption of intracellular nutrients; bioavailability is enhanced when cells are lysed or autolyzed. Beta-glucan and mannan fractions remain largely intact through the GI tract, functioning as fermentable substrates (prebiotic effect) rather than being directly absorbed. Strain-specific nutritional data for RC 12 is not independently published in the peer-reviewed literature; figures above represent best estimates extrapolated from S. cerevisiae species data.

## Dosage & Preparation

No clinically studied dosages for Saccharomyces cerevisiae RC 12 were identified. Related strains like CNCM I-3856 used daily supplementation in digestive simulations, with exact CFU counts not specified. Standardization focused on live viable cells rather than extracts or powders. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Saccharomyces cerevisiae strains are generally recognized as safe (GRAS) for healthy adults, and RC 12 has no documented serious adverse events in the available literature, though formal toxicology studies specific to this strain are limited. Individuals with yeast allergies, Crohn's disease, or compromised [immune system](/ingredients/condition/immune-support)s should exercise caution, as Saccharomyces species can rarely cause fungemia in severely immunocompromised patients. Concurrent use with antifungal medications such as fluconazole may reduce viability and efficacy of the yeast strain. Pregnancy and breastfeeding safety has not been specifically evaluated for the RC 12 strain, so use during these periods is not recommended without medical supervision.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically for Saccharomyces cerevisiae RC 12 were identified. Evidence comes from in vitro M-SHIME gut simulation models (n=3 donors, 18-day treatment) and preclinical vaginal infection models using related strain CNCM I-3856. Human safety data for CNCM I-3856 confirmed general tolerability with no serious side effects reported, though specific study details and PMIDs were not provided.

## Historical & Cultural Context

No historical traditional medicine use was documented for Saccharomyces cerevisiae RC 12 or specific clinical strains. General S. cerevisiae appears in fermented foods like rice Chhang without medicinal context, with [probiotic](/ingredients/condition/gut-health) applications representing modern isolation rather than ancient traditional use.

## Synergistic Combinations

Bifidobacterium strains, Lactobacillus species, Prebiotic fibers, Short-chain fatty acid precursors, [Digestive enzyme](/ingredients/condition/gut-health)s

## Frequently Asked Questions

### What is Saccharomyces cerevisiae RC 12 and how is it different from brewer's yeast?

Saccharomyces cerevisiae RC 12 is a proprietary strain of baker's/brewer's yeast selected specifically for its gut-modulating properties, distinguishing it from generic brewer's yeast used in fermentation or nutritional supplementation. Unlike standard brewer's yeast, RC 12 has been characterized for its ability to promote Bifidobacterium and Lactobacillus growth and to disrupt ETEC membrane integrity, effects not documented for uncharacterized commercial yeast preparations.

### Does Saccharomyces cerevisiae RC 12 increase short-chain fatty acid production?

In vitro simulated gut fermentation models have shown that RC 12 supplementation increases production of short-chain fatty acids including butyrate and propionate by stimulating the growth of SCFA-producing bacteria such as Bifidobacterium and Lactobacillus. These SCFAs lower colonic pH and serve as primary energy substrates for colonocytes, supporting gut barrier function. However, these findings are based solely on in vitro models, and human clinical confirmation is currently lacking.

### Can Saccharomyces cerevisiae RC 12 fight E. coli infections?

Laboratory evidence suggests RC 12 reduces the viability of enterotoxigenic Escherichia coli (ETEC) by damaging bacterial outer membrane integrity and suppressing virulence gene expression, including genes encoding heat-labile and heat-stable enterotoxins. This has been demonstrated in digestive simulation models rather than human infection trials, so it cannot be claimed as a treatment for E. coli infections. The data is promising for gut-protective applications but requires clinical validation before therapeutic conclusions can be drawn.

### Is Saccharomyces cerevisiae RC 12 safe for people with yeast sensitivities?

Individuals with confirmed yeast allergies or hypersensitivity to Saccharomyces species should avoid RC 12, as cross-reactivity with yeast allergens is plausible even with proprietary strains. People with inflammatory bowel disease, particularly Crohn's disease, are known to mount elevated immune responses to Saccharomyces cerevisiae antigens, including anti-Saccharomyces cerevisiae antibodies (ASCA), and should consult a physician before use. No strain-specific allergy data for RC 12 has been published.

### What dosage of Saccharomyces cerevisiae RC 12 is recommended?

No standardized clinical dosage has been established for Saccharomyces cerevisiae RC 12, as human dose-ranging trials have not been published for this specific strain. Dosing in supplement formulations typically follows general yeast-based probiotic conventions, often ranging from 500 mg to 1,000 mg per day, but these figures are not validated by RC 12-specific efficacy or safety data. Consumers should follow manufacturer guidance and consult a healthcare provider for personalized recommendations.

### What does clinical research show about Saccharomyces cerevisiae RC 12 compared to other probiotic strains?

Saccharomyces cerevisiae RC 12 has demonstrated prebiotic-like activity in in vitro studies, promoting growth of beneficial Bifidobacterium and Lactobacillus species while increasing short-chain fatty acid production. However, most evidence is preclinical; human clinical trials are limited compared to well-studied strains like Lactobacillus rhamnosus or Bifidobacterium longum. The strain shows promise in simulated gut models for pathogenic bacteria reduction, but real-world efficacy in humans requires further investigation.

### Is Saccharomyces cerevisiae RC 12 safe for children and the elderly?

Saccharomyces cerevisiae RC 12 is generally recognized as safe, though specific pediatric and geriatric safety data are limited in published literature. As a non-pathogenic yeast strain, it presents minimal risk for immunocompetent populations, but elderly individuals or those with compromised immune systems should consult a healthcare provider before use. Children may benefit from probiotic support, but age-appropriate dosing and medical clearance are recommended.

### How does Saccharomyces cerevisiae RC 12 support vaginal and digestive health differently?

Saccharomyces cerevisiae RC 12 inhibits Gardnerella bacterial load by up to 90% and disrupts biofilm formation, making it relevant for vaginal dysbiosis support, while simultaneously promoting commensal bacteria growth and SCFA production in the digestive tract. This dual mechanism addresses both local vaginal microbiota imbalance and systemic gut barrier function through a single strain. The biofilm-disrupting property is particularly valuable since Gardnerella forms protective biofilms that resist conventional treatments.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*